Name: Actovegin ® 5ml Solution - Limitless Life Nootropics
Price: 39.99 USD
Availability: InStock

Product Description

Actovegin is a highly purified calf blood hemoderivative produced using advanced ultrafiltration techniques. The resulting solution contains low molecular weight substances including essential amino acids, metabolic intermediates, electrolytes, and bioactive oligosaccharides that naturally occur in biological systems.

This liquid formulation in sealed glass ampoules supports in vitro research into cellular energy metabolism, mitochondrial function, and glucose uptake mechanisms. Pharmaceutical-grade quality ensures consistent results for laboratory investigations. Strictly for research applications only.

Specifications

Container:: 5ml Glass Ampoule
Active Ingredient:: Deproteinized calf blood hemoderivative
CAS Number:: 63748-11-8
Composition:: Amino acids, oligosaccharides, nucleotides, glycolipids, inositol phospho-oligosaccharides
Storage Conditions:: Store in a dark place at a temperature not exceeding 25°C
Manufacturing Method:: Highly purified hemodialysate extracted by ultrafiltration

Research

Actovegin’s complex composition of over 200 bioactive compounds below 5 kDa has generated extensive laboratory research across multiple biological pathways. Studies examine its effects on cellular energy metabolism, neuroprotection, inflammation modulation, and tissue regeneration mechanisms.

Neurological Research

Actovegin demonstrates neuroprotective properties through multiple pathways in laboratory studies. The compound increases neuronal survival up to 2.4-fold compared to untreated cultures[1].

Research shows significant protection against neuronal apoptosis by reducing activated caspase-3 levels when neurons face neurotoxic challenges. The compound enhances excitatory synaptic connections by increasing vesicular glutamate transporter 1 protein expression[2].

In ischemic models, Actovegin improves oxygen utilization and glucose uptake in brain tissue. Studies demonstrate normalized metabolic parameters including glucose, lactate, and ATP concentrations under hypoxic conditions[3].

Metabolic Studies

The compound exhibits insulin-like activity by stimulating glucose transport and pyruvate dehydrogenase activity. Research confirms enhanced mitochondrial oxidative phosphorylation in muscle fiber preparations[4].

Actovegin contains glucose at fourfold higher levels compared to physiological serum concentrations. Essential inorganic substances including potassium, chloride, sodium, and phosphate appear at up to tenfold higher levels, supporting ATP formation pathways.

Anti-inflammatory Research

Laboratory studies show selective anti-inflammatory effects, particularly against PMA-induced inflammation. The compound reduces IL-1beta secretion from immune cells in a concentration-dependent manner[4].

Research indicates B-cell mediated inflammatory response modulation rather than monocyte-mediated pathways. The mechanism involves supporting ICEberg protein synthesis, which inhibits caspase-1 and reduces inflammatory cytokine generation.

Antioxidant Mechanisms

Actovegin demonstrates potent antioxidant effects by reducing reactive oxygen species levels in cultured neurons and immune cells. The compound supports cellular antioxidative defense systems through concentration-dependent ROS reduction[1].

High levels of cystathionine, a precursor to cysteine synthesis and glutathione formation, contribute to antioxidant function. Research shows support for both enzymatic and non-enzymatic antioxidant systems.

Tissue Research

Studies demonstrate effectiveness in promoting tissue repair across multiple tissue types. In blood preservation research, it promotes restoration of erythrocyte morphological and functional characteristics after storage[5].

The compound supports tissue regeneration through enhanced cellular energy metabolism and improved oxygen utilization. Research shows enhanced proliferation of muscle precursor cells, suggesting applications in skeletal muscle studies[4].

References

M. W. Elmlinger, M. Kriebel, and D. Ziegler, “Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro,” Springer Science and Business Media LLC, Oct. 2011. doi: 10.1007/s12017-011-8157-7. Available: https://doi.org/10.1007/s12017-011-8157-7
A. Guekht, I. Skoog, S. Edmundson, V. Zakharov, and A. D. Korczyn, “ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin),” Ovid Technologies (Wolters Kluwer Health), May 2017. doi: 10.1161/strokeaha.116.014321. Available: https://doi.org/10.1161/strokeaha.116.014321
S. Meilin, F. Machicao, and M. Elmlinger, “Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia,” Wiley, May 2014. doi: 10.1111/jcmm.12297. Available: https://doi.org/10.1111/jcmm.12297
F.-X. Reichl et al., “Actovegin® reduces PMA-induced inflammation on human cells,” Springer Science and Business Media LLC, May 2020. doi: 10.1007/s00421-020-04398-2. Available: https://doi.org/10.1007/s00421-020-04398-2
O. K. Gulevskyy, “RESTORATION OF THE STRUCTURAL AND FUNCTIONAL STATE OF ERYTHROCYTES AFTER HYPOTHERMIC STORAGE USING HUMAN CORD BLOOD LOW-MOLECULAR FRACTION AND THE DRUG ACTOVEGIN,” National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications), Dec. 2021. doi: 10.15407/biotech14.06.044. Available: https://doi.org/10.15407/biotech14.06.044